Foto del docente

Marco Rinaldo Oggioni

Full Professor

Department of Pharmacy and Biotechnology

Academic discipline: BIO/19 Microbiology

Curriculum vitae

Download Curriculum Vitae (.docx 29KB )

Curriculum vitae of MARCO RINALDO OGGIONI, born at Legnano (Italy) on January 1st 1965. Italian and German citizen.

 

CONTACT

1) Dipartimento di Farmacia e Biotecnologie FaBiT, Via Irnerio 42, 40126 Bologna +39 051 20 9 1285 marco.oggioni@unibo.it [mailto:marco.oggioni@unibo.it]

2) Dept of Genetics and Genome Biology, University of Leicester, Leicester LE1 7RH, UK, +44 (0)116 252 2261 mro5@leicester.ac.uk [mailto:mro5@leicester.ac.uk]

 

POSITION

2020- Professore Ordinario (BIO/19), Dipartimento di Farmacia e Biotecnologie FaBiT, Universita’ di Bologna, Bologna, Italy.

2013- Chair in Microbial Genetics, Department of Genetics and Genome Biology, University of Leicester, Leicester.

 

PREVIOUS POSITIONS

2015-2021 Honorary Consultant Microbiologist, University Hospitals of Leicester NHS Trust, Leicester, UK.

1993-2013 Consultant Microbiologist (Dirigente Medico), Siena University Hospital (Azienda Ospedaliera Universitaria Senese), and Professor of Microbiology (non-tenure) at the Medical School, University of Siena (Italy).

 

EDUCATION

2023- Registrazione con I‘Ordine dei Medici di Bologna

2022- Steering group Italian Society of General Microbiology SIMGBM

2019- Fellow of the Royal Society of Biology FRSB

2019- Fellow of the International Society of Antimicrobial Chemotherapy FISAC

2016-21 Affiliate member Royal College of Pathologists

2015-18 Chair of the ESCMID Study Group for Infectious Diseases of the Brain (ESGIB)

2015- Fellow of the UK Higher Education Academy FHEA

2015-22 Registration with the UK General Medical Council with Specialist registration in Medical Microbiology

1994 Specialisation Degree in Microbiology and Virology, University of Siena, Italy

1990 Medical Degree, Medical School of the University of Verona, Italy

 

GRANTS (current)

IT

2024-26 GSK Contract Research 2, In vivo models for pathogen research. PI.

2024-27 EU grant MACS GAP-101131231 AMRAMR. PI

2023-25 PRIN PNRR grant P2022M8KYE. The innate immune reaction to invasive infection in human organs. PI.

2023-26 Cystic Fibrosis Foundation FFC grant FFC#13/2023. Aptides for prevention of infections. CoI.

2023-26 GSK Contract Research 1, In vivo models for pathogen research. PI.

2023-26 Ricerca Finalizzata RF-2021-12375437. RNA vaccine for S. pneumoniae and MTB. CoI.

2022-25 EU grant PNRR PE13 INF-ACT PE00000007. Emerging Infectious Diseases. CoI

2022-25 PRIN 2020 grant 202089LLEH. The CoDiCo (colonisation to disease concepts) project. PI.

2022-23 Fondazione del Monte. Migratory birds and risk of viral spillover. CoI.

UK

2022-27 BRC NIHR203327. Leicester NIHR Biomedical Research Centre. Contributor.

2022-25 BHF Project Grant PG/22/11117. Epigenetic phase variation of periodontal bacteria CoI.

2019-23 Australian Research Council DP190102980. Bacterial metabolism and cell-to-cell signalling. CoI.

 

CLINICAL TRIALS:

2023-26 MOISE, CE-AVEC:668/2023/Sper/AOUBo of 19/10/2023. End date 18/10/2026. Scientific responsible.

2021-25 TIMOLD, ClinicalTrials.gov NCT05255042, REC: 21/PR/0287, IRAS 293486. End date: 31/12/2025. Chief Invest.

2018-25 TIMID, ClinicalTrials.gov NCT04620824, REC 18/EM/0057, IRAS 219992, End date: 31/12/2025. Chief Invest.

 

RESEARCH INTERESTS: Analysis of the molecular basis of mechanisms involved in the interaction of bacterial pathogens with their environment - the human host - by use of genomic tools and the study of microbial physiology. Most recent contributions were the identification of epigenetic control of bacterial gene expression and the identification of bacterial replication within a subset of tissue macrophages prior to invasive disease. Additional interests include investigation into the molecular determinants of antimicrobial drug resistance and mechanisms governing mobile genetic elements.

 

PUBLICATIONS (orcid.org/0000-0003-4117-793X)

publications: 152

h index: 57

Latest news

At the moment no news are available.